The selective MMP inhibitor ND-322 in a melanoma orthotopic mouse model can inhibit tumor growth and metastatic processes by targeting MMP-2 and MT1-MMP, providing a new avenue for adjuvant treatment options for aggressive melanoma (150). This evidence concerns the gene MMP14 and neoplasm.